Current views on the use of long-acting anticholinergic drug tiotropium in the treatment of bronchial asthma among children
https://doi.org/10.24411/2500-1175-2020-10010
- Р Р‡.МессенРТвЂВВВВВВВВжер
- РћРТвЂВВВВВВВВнокласснРСвЂВВВВВВВВРєРСвЂВВВВВВВВ
- LiveJournal
- Telegram
- ВКонтакте
- РЎРєРѕРїРСвЂВВВВВВВВровать ссылку
Full Text:
Abstract
Despite treatment of bronchial asthma, in accordance with current recommendations, inhaled corticosteroids as monotherapy or in combination with long-acting β2 agonists, at least 40% of patients fail to achieve disease control. The long-acting anticholinergic drug Tiotropium (through a liquid inhaler Respimat) is recommended for use in adults and children over S years of age by experts from GINA, the Russian respiratory society and the Pediatric respiratory society as an additional strategy for achieving bronchial asthma control. The article highlights the pharmacological properties of Tiotropium and its mechanism of action in asthma. The results of the author's own research on the use of Tiotropium in children S–11 years of age with moderate and severe bronchial asthma in real clinical practice are presented.
About the Author
E. V. Churyukina
Rostov State Medical University;
Kuban State Medical University
Russian Federation
Russian Federation
Ella V. Churyukina, candidate of medical sciences, head of the Department of allergic and autoimmune diseases Rostov State Medical University, associate Professor of the Department of clinical immunology, allergology and laboratory diagnostics Kuban State Medical University
4/1 Bashkirskaya str., ap. 9, Rostov-on-don, 344068
References
1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Updated 2019. Available at: https://www.ginasthma.org Global Strategy for Asthma Management and Prevention. Revised 2019 // www.ginasthma.com
2. Masoli M., Fabian D., Holt S., Beasley R. Global Initiative for Asthma (GINA) Program. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004; 59: 469- 478.
3. Bateman E.D., Boushey H.A., Bousquet J., Busse W.W., Clark T.J.H., Pauwels R.A., et al. Can guidelinedefined asthma control be achieved? The Gaining Optimal Asthma Control study. Am J Respir. Crit Care Med 2004; 170: 836-844.
4. Demoly P., Paggiaro P., Plaza V., Bolge S.C., Kannan H., Sohier B. et al. Prevalence of asthma control among adults in France, Germany, Italy, Spain and the UK. Eur. Respir. Rev 2009; 18: 105-112.
5. Partridge M.R., Dal Negro R.W., Olivieri D. Understanding patients with asthma and COPD: insights from a European study. Prim Care Respir J 2011; 20: 315-323.
6. Custovic A., Johnston S.L., Pavord I., Gaga M., Fabbri L., Bel E.H. et al. EAACI position statement on asthma exacerbations and severe asthma. Allergy 2013; 68: 1520-1531.
7. Belgrave D.C.M., Buchan I., Bishop C., Lowe L., Simpson A., Custovic A. Trajectories of lung function during childhood. Am J Respir Crit Care Med 2014; 189: 1101-1109.
8. Lemanske R.F. Jr, Mauger D.T., Sorkness C.A., Jackson D.J., Boehmer S.J., Martinez F.D. et al. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N Engl J Med 2010; 362: 975-985.
9. Geppe N.A., Kolosova N.G., Arkhipov V.V., Mizernitskii Yu.L., Blokhin B.M. i dr. Primenenie tiotropiya v bazisnoi terapii bronkhial'noi astmy u detei. Zaklyuchenie Soveta ekspertov Pediatricheskogo respiratornogo obshchestva // Voprosy prakticheskoi pediatrii. 2017, tom 12, №4, s. 77-84. https://doi.org/10.20953/1817-7646-2017-4-77-84.
10. Churyukina E.V., Lebedenko A.A., Galkina G.A., Dudareva M.V., Levkovich M.A. Kliniko-immunologicheskie osobennosti fenotipa bronkhial'noi astmy s ozhireniem u detei // Allergologiya i immunologiya v pediatrii. 2018, №3 (54), s. 14-20.
11. Kistemaker L.E., Gosens R. Acetylcholine beyond bronchoconstriction: roles in inflammation and remodeling. Trends in Pharmacological Sciences 2015 Mar; 36(3): 164-171.
12. Nadel J.A., Barnes P.J. Autonomic regulation of the airways. Ann. Rev. Med. 1984, v. 35, r. 451-467.
13. Nenasheva N.M. Bronkhial'naya astma. Sovremennyi vzglyad na problemu / N.M. Nenasheva. - M.: GEOTAR-Media, 2018. - 304 s.: il. - (Seriya «Biblioteka vracha-spetsialista»)
14. Disse B., Reichl R., Speck G. et al. Ba S73 BR, a novel long-acting anticholinergic bronchodilator. Life Sci. 1993, v. 52, r. 537-544.
15. Joos G.F. Potential usefulness of inhibiting neural mechanisms in asthma. Monaldi Arch. Chest. Dis. 2000, v. 55, r. 411-414.
16. Mak J.C.W., Barnes P.J. // Am. Rev. Respir. Dis. 1990.V. 141.P. 1559.
17. Fryer A.D., Jacoby D.B. // Am. J. Respir. Crit. Care Med.1998. V. 158. Suppl. 2. P. S154.
18. Coulson F.R., Fryer A.D. Muscarinic acetylcholine receptors and airway diseases. Pharmacol. Ther. 2003, v. 98, r. 59-69.
19. Barnes P.J. Pharmacologic Principles. In Murray and Nadel's Textbook of Respiratory Medicine, 5th ed. 2010. p. 159-199.
20. Churyukina E.V., Vashchenko T.B., Sizyakina L.P. Otsenka effektivnosti i bezopasnosti ronkoleikina v kompleksnom lechenii bol'nykh gormonozavisimoi bronkhial'noi astmoi tyazhelogo techeniya. Terra Medica Nova. 2004. №4 (36). S. 18.
21. Barnes P.J. Tiotropium bromide. Expert Opin. Investig. Drugs. 2001, v. 10, r. 733-740.
22. Disse B., Speck G.A., Rominger K.L. et al. Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease. Life Sci. 1999, v. 64, r. 457-464.
23. Avdeev S.N. Rol' antikholinergicheskikh preparatov pri obstruktivnykh zabolevaniyakh legkikh. Consilium medicum. 2002; Tom 4, №9: 478-485.
24. Instruktsiya po primeneniyu lekarstvennogo preparata dlya meditsinskogo primeneniya Spiriva® Respimat®. Dostupno po ssylke: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=41ef4956-7fb7-463c-8a2b-f5d4be30896b&t= Ssylka aktivna na 06.02.2020.
25. Ushkalova E.A. Antikholinergicheskie preparaty dlitel'nogo deistviya v lechenii bronkhial'noi astmy. Farmateka. Pul'monologiya 2016; 4 (317): 34-40.
26. Ohta S., Oda N., Yokoe T. et al. Effect of tiotropium bromide on airway inflammation and remodelling in a mouse model of asthma. Clin.Exp. Allergy. 2010, v. 40, r. 1266-1275.
27. Buels K.S., Jacoby D.B., Fryer A.D. Non-bronchodilating mechanisms of tiotropium prevent airway hyperreactivity in a guinea-pig model of allergic asthma. Br. J. Pharmacol. 2012, v. 165, r. 1501-1514.
28. Raemdonck K. et al. Thorax 2012; 67(1): 19-25.
29. Bos I., Gosens R., Zuidhof A. et al. Inhibition of allergen-induced airway remodeling by tiotropium and budesonide: a comparison. Eur. Respir. J. 2007, v. 30, r. 653-661.
30. Nenasheva N.M. Novye vozmozhnosti dostizheniya kontrolya astmy s pomoshch'yu tiotropiya bromida. Effektivnaya farmakoterapiya. 29/2014, № 2, s. 2-10.
31. ArkhipovV.V., ArkhipovaD.E., LazarevaN.B. Novye ingalyatsionnye ustroistva dlya terapii khronicheskoi obstruktivnoi bolezni legkikh. Pul'monologiya. 201S; 26 (3): 352-356.
32. Keating G.M. Tiotropium Respimat Soft Mist™ inhaler: a review of its use in chronic obstructive pulmonary disease. Drugs. 2014; 74 (15): 1801-1816.
33. Churyukina E.V. Assessment of the functional status and application of long-acting m-anticholinergic in children with bronchial asthma in real clinical practice // European Academy of Allergy and Clinical Immunology. EAACI Congress 1-5 June 2019, Lisbon, Portugal. Abstract TPO805. Wiley-Allergy. P. 456 www.eaaci.org
34. Kozhin A.A., Popova V.A., Puzikova O.Z., Churyukina E.V., Goloshubova E.A. Osobennosti funktsional'nogo sostoyaniya detei grupp ekologicheskogo riska, aspekty ikh immunnogo statusa i vozmozhnosti vosstanovitel'noi terapii // Allergologiya i immunologiya v pediatrii. 2019. №1 (56). S. 28-36.
35. Bryan C. Husta et al. Chest. 2017 Dec; 152(6): 1296-1305. Published online 2017 Aug 31.
36. Qian C.J., Coulombe J., Suissa S., Ernst P. Pneumonia risk in asthma patients using inhaled corticosteroids: a quasi-cohort study. Br J Clin Pharmacol; (2017) 83; 2077-2086. https://doi.org/10.1111/bcp.13295
37. Suissa S., Kezouh A., Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am J Med 2010; 123: 1001-1006.
38. Juniper E.F., O'Byrne P.M., Guyatt G.H. et al. Development and validation of a questionnaire to measure asthma control. Eur. Respir. J. 1999; 14: 902-907.
39. Nathan R.A., Sorkness C.A., Kosinski M. et al. Development of the asthma control test: a survey for assessing asthma control. J. Allergy Clin. Immunol.2004; 113: 59-65.
40. Vollmer W.M., Markson L.E., O'Connor E. et al. Association of asthma control with health care utilization and quality of life. Am. J. Respir. Crit Care Med. 1999; 1S0: 1647-1652.
41. Boulet L.-P., Boulet V., Milot J. How should we quantify asthma control? Aproposal. Chest 2002; 122: 2217-2223.
42. Belevskii A.S. Test kontrolya astmy - «novaya igrushka» ili vazhnyi instrument? Atmosfera. Pul'monologiya i allergologiya 2005; 1: 1-2.
43. Ogorodova L.M., Deev I.A., Selivanova P.A. GINA 200S: Kontrol' astmy kak osnovnaya tsel' lecheniya i kriterii effektivnosti terapii. Pul'monologiya 2007; 6: 42-45.
44. Churyukina E.V., Nikanorova M.V. Diagnosticheskii algoritm spirometricheskoi verifikatsii diagnoza bronkhial'noi astmy. Allergologiya i immunologiya. 2016. T. 17. №2. S. 131-132.
45. Lai C.K., De Guia T.S., Kim Y.Y. et al. Asthma control in the Asia-Pacific region: the Asthma Insights and Reality in Asia-Pacific Study. J. Allergy Clin. Immunol. 2003; 111: 263-268.
46. Juniper E.F., O'Byrne P.M., Guyatt G.H. et al. Development and validation of a questionnaire to measure asthma control. Eur. Respir. J. 1999; 14: 902-907.
47. Juniper E.F., O'Byrne P.M., Roberts J.N. Measuring asthma control in group studies: do we need airway calibre and res cue β2-agonist use? Respir. Med. 2001; 95: 313-323.
48. Svensson K., Mork A.C., Juniper E.F. ACQ - is five out of seven items acceptable in large clinical studies? Qual. Life Res. 2003; 12: 771.
49. Juniper E.F., Bousquet J., Abetz L. et al. Identifying «wellcontrolled» and «not wellcontrolled» asthma using the Asthma Control Questionnaire. Respir. Med. 2006; 100: 616-621.
50. Bateman E.D., Bousquet J., Braunstein G.L. Is overall asthma control being achieved? A hypothesis-generating study. Eur. Respir. J. 2001, v. 17, p. 589-595.
Review
For citations:
Churyukina E.V. Current views on the use of long-acting anticholinergic drug tiotropium in the treatment of bronchial asthma among children. Allergology and Immunology in Paediatrics. 2020;(3):29-38. (In Russ.) https://doi.org/10.24411/2500-1175-2020-10010
Views:
164
ISSN 2500-1175 (Print)
ISSN 2712-7958 (Online)
ISSN 2712-7958 (Online)
Email this article 